Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enumeral Biomedical Holdings Inc.

Taking checkpoint inhibition to the next level

This article was originally published in Start Up

Executive Summary

Checkpoint inhibitors have caused a sensation in oncology in recent years, but biotech Enumeral Biomedical Holdings Inc. is setting its sights on the Achilles' heel of the new antibodies – the high failure rate – using a discovery platform that employs cells from human biopsies, rather than more commonly used rodent models.

You may also be interested in...



Keeping Track: Venclexta Approved; Opdivo, Atezolizumab Seek Additional Indications

The latest drug development news and highlights from our FDA Performance Tracker.

Video: Enumeral Aspires To Take PD-1 Inhibition To The Next Level

In an interview at the recent Biotech Showcase, CEO Arthur Tinkelenberg explains his company’s approach to developing the next generation of checkpoint inhibitors.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel